Burrill & Company

Neos Therapeutics, Inc. is a pharmaceutical company based in Grand Prairie, Texas, focused on the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD). Utilizing its proprietary drug delivery technology platform, Neos produces extended-release medications in various forms, including orally disintegrating tablets and liquid suspensions. Its product lineup features Adzenys XR-ODT and Adzenys ER, both amphetamine-based treatments, and Cotempla XR-ODT, a methylphenidate formulation, all designed to address ADHD symptoms. Additionally, the company markets generic Tussionex, a hydrocodone and chlorpheniramine polistirex oral suspension for cough relief. Neos is also developing NT0502, a clinical-stage candidate aimed at treating chronic sialorrhea associated with certain neurological conditions. The company operates primarily in the United States and is committed to creating high-quality products that meet significant medical needs.

Nora Therapeutics is a biopharmaceutical company based in Palo Alto, California, focused on developing therapeutics for unmet needs in reproductive medicine. Founded in 1992, the company's lead product, NT100, is a novel biologic agent designed to mimic a naturally occurring protein in the female reproductive tract. NT100 aims to improve pregnancy success rates and outcomes by optimizing maternal-fetal immune tolerance, particularly for women with a history of unexplained recurrent miscarriage or multiple unsuccessful in vitro fertilization (IVF) procedures. This optimization is intended to enhance embryo implantation and maintain pregnancy.

Neos Therapeutics, Inc. is a pharmaceutical company based in Grand Prairie, Texas, focused on the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD). Utilizing its proprietary drug delivery technology platform, Neos produces extended-release medications in various forms, including orally disintegrating tablets and liquid suspensions. Its product lineup features Adzenys XR-ODT and Adzenys ER, both amphetamine-based treatments, and Cotempla XR-ODT, a methylphenidate formulation, all designed to address ADHD symptoms. Additionally, the company markets generic Tussionex, a hydrocodone and chlorpheniramine polistirex oral suspension for cough relief. Neos is also developing NT0502, a clinical-stage candidate aimed at treating chronic sialorrhea associated with certain neurological conditions. The company operates primarily in the United States and is committed to creating high-quality products that meet significant medical needs.

BetterDoctor, Inc. is a technology company based in San Francisco, founded in 2011, that focuses on improving healthcare access by providing web and mobile applications for users to find doctors. Its platform allows individuals to search for healthcare providers based on their specific needs and insurance plans, offering a directory of verified doctors. BetterDoctor also serves health plans and systems by validating and delivering accurate provider data through its API, supporting numerous companies and developers in enhancing their healthcare offerings. By enabling real-time appointment scheduling and ensuring the accuracy of doctor information, BetterDoctor aims to simplify the process of finding qualified healthcare professionals, thereby improving patient outcomes. As of June 2018, BetterDoctor operates as a subsidiary of Quest Analytics, L.L.C.

NewBridge Pharmaceuticals Ltd. is a specialty therapeutics company based in Dubai, United Arab Emirates, established in 2007. The company focuses on addressing unmet medical needs in the Middle East, Africa, Turkey, and Caspian regions through the in-licensing, acquisition, registration, and commercialization of pharmaceuticals, biologics, and medical diagnostics. NewBridge offers a diverse portfolio of products that includes oncology and supportive care medications such as Abstral for cancer pain management, Clasteon for bone metastasis and hypercalcemia, and Sancuso for preventing chemotherapy-induced nausea. Additionally, it provides metabolic care treatments like Gliconorm for diabetes and PYLERA for H. pylori eradication. The company's offerings also extend to CNS care products, including Vimpat for seizures and Neupro for Parkinson's disease, as well as immunology care solutions like Cimzia for rheumatoid arthritis. By focusing on therapeutic areas such as oncology, diabetes, and metabolic disorders, NewBridge Pharmaceuticals aims to support patients with critical health challenges in its target regions.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

Strand Life Sciences Pvt Ltd. is a clinical diagnostics and genomic profiling company based in Bengaluru, India, specializing in the development and marketing of diagnostic tests for cancer and inherited diseases. Founded in 2000, the company offers a wide range of services, including diagnostics for oncology, genetics, fertility, women's health, infectious diseases, and general wellness. Strand provides advanced bioinformatics solutions, such as variant curation and interpretation platforms, along with its StrandOmics software for actionable insights from genomic data. The firm operates a DNA sequencing lab and has established partnerships with over 100 hospitals in India, expanding its reach into the US market. Strand's innovative software, including GeneSpring and Avadis, is utilized by 1,400 research institutions worldwide. The company emphasizes personalized medicine by identifying hereditary cancer risks and enabling tailored surveillance and risk-reduction strategies for patients. With a team of approximately 200 employees, Strand Life Sciences continues to grow in response to increasing demand for its genomic testing and interpretation services.

Odyssey Thera, Inc. is a biopharmaceutical company based in San Ramon, California, dedicated to identifying and developing innovative therapies for cancer treatment. The company employs a cellular pharmacology strategy to decipher biologically-relevant pathways in living human cells, enhancing the processes of target and drug discovery. Odyssey Thera's product pipeline features small molecule inhibitors that target crucial signaling nodes in human cancer cells. Originally incorporated as Odyssey Pharmaceuticals in 2002, the company has evolved to focus on advancing methods for environmental chemical toxicity assessment alongside its therapeutic development efforts.

MabVax Therapeutics is a clinical stage biopharmaceutical company dedicated to the development and commercialization of innovative anti-cancer immunotherapies. The company leverages two main technology platforms: one involves proprietary vaccines developed at Memorial Sloan-Kettering Cancer Center, with two lead cancer vaccines currently in Phase II clinical trials targeting soft tissue sarcoma and ovarian cancer, both of which have received substantial federal grant support. The second platform is an internally developed human antibody discovery system, which focuses on the immune responses from patients who have been vaccinated against specific cancers. MabVax's leading human antibody candidate is in preclinical evaluation for potential applications in treating colon, pancreatic, and breast cancers, also backed by federal funding. The company aims to address significant unmet needs in cancer treatment through its innovative approaches and pipeline of human monoclonal antibody products.

Cobalt Technologies is a biotechnology company founded in 2005 and headquartered in Mountain View, California. The company specializes in developing innovative technologies for the production of biofuels, particularly focusing on next-generation bio n-butanol. Cobalt's advancements enable the creation of low-cost, commercial-scale biobutanol, which serves as a sustainable alternative to petroleum-based products. This bio-based chemical can be utilized in a wide range of applications, including fuels, jet fuel, bio-based plastics, synthetic rubber, paints, adhesives, and solvents. By providing cost-effective substitutes to traditional petroleum-derived chemicals, Cobalt Technologies aims to contribute to cleaner burning fuels and a reduced environmental impact.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

Waterstone Pharmaceuticals, Inc. is a private company engaged in the research, development, and commercialization of drugs aimed at treating liver, gastrointestinal, kidney, and metabolic diseases. Founded in 2009, it is based in Wuhan, China, and operates additional offices in Tianmen, China. The company specializes in the development of proprietary new chemical entities and offers custom development and manufacturing services, including a range of active pharmaceutical ingredients (APIs), intermediates, and antibody drug conjugates. Waterstone Pharmaceuticals is dedicated to advancing innovative treatment options to address significant medical needs in these areas.

AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing innovative treatments for rare cancers. The company is working on a proprietary gel formulation of mechlorethamine hydrochloride aimed at treating early-stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If successful, this investigational drug would be the first topical mechlorethamine product available to alleviate the signs and symptoms associated with this condition. In addition to its primary focus on CTCL, Ceptaris is also advancing YT-1006, an NMDA antagonist designed for treating neuropathic pain while mitigating side effects through a unique stereochemistry approach.

WhiteGlove Health, Inc. is a mobile healthcare provider based in Austin, Texas, specializing in delivering primary care, preventative medical services, and support for individuals with chronic conditions directly at home and work sites. Established in 2006, the company has expanded its services to major locations including Dallas/Fort Worth, Houston, San Antonio, and Phoenix. WhiteGlove Health focuses on creating a high-quality healthcare experience while simultaneously reducing costs for health plans through decreased insurance claims and minimized unnecessary medical utilization. The clinical team, composed of board-certified nurse practitioners and registered nurses, provides comprehensive care, including at-home visits and telephonic support, particularly for high-risk patients under Medicare and Medicaid. The company’s Value-Based Care division, launched in 2014, emphasizes proactive management to reduce hospital admissions and improve patient outcomes. Additionally, WhiteGlove Health enhances its service offerings through a partnership with Glenridge Healthcare Solutions, which provides advanced analytics and technology solutions, further promoting efficient healthcare delivery across the nation.

WaveTec Vision, founded in 1997 and located in Aliso Viejo, California, specializes in advanced wavefront measurement technology for cataract surgery. The company's proprietary intraoperative aberrometer system, ORange, allows surgeons to measure the eye and enhance surgical outcomes in real-time. By facilitating the convergence of refractive and cataract surgery, WaveTec Vision aims to improve the overall efficacy and precision of these procedures, ultimately benefiting patient care and satisfaction.

Cobalt Technologies is a biotechnology company founded in 2005 and headquartered in Mountain View, California. The company specializes in developing innovative technologies for the production of biofuels, particularly focusing on next-generation bio n-butanol. Cobalt's advancements enable the creation of low-cost, commercial-scale biobutanol, which serves as a sustainable alternative to petroleum-based products. This bio-based chemical can be utilized in a wide range of applications, including fuels, jet fuel, bio-based plastics, synthetic rubber, paints, adhesives, and solvents. By providing cost-effective substitutes to traditional petroleum-derived chemicals, Cobalt Technologies aims to contribute to cleaner burning fuels and a reduced environmental impact.

Virdia, formerly known as HCL CleanTech, is a prominent developer specializing in the conversion of lignocellulosic biomass into cellulosic sugars and lignin for applications in the renewable chemicals, bio-energy, and nutrition sectors. Utilizing its proprietary CASE™ process, the company transforms a diverse range of feedstocks, including wood, energy crops, and agricultural residues, into highly refined sugars and lignin. This innovative low-temperature process achieves high yields of sugars from biomass while maintaining a minimal environmental impact through the near complete recycling of acids and solvents used during production. Virdia is guided by an experienced management team with extensive backgrounds in corn processing, chemicals, and biochemicals.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company offers a range of products, including BIVIGAM and ASCENIV, both intravenous immune globulin therapies for primary humoral immunodeficiency, as well as Nabi-HB, which is used for acute exposure to Hepatitis B. ADMA is also involved in the development of additional plasma-derived therapeutics, particularly targeting infections like S. pneumonia. To support its operations, the company runs FDA-licensed source plasma collection facilities known as ADMA BioCenters, which contribute to the supply of plasma necessary for its product manufacturing. ADMA Biologics distributes its products through independent distributors, sales agents, specialty pharmacies, and other healthcare providers. Founded in 2004 and based in Ramsey, New Jersey, ADMA is dedicated to serving niche patient populations, particularly those with compromised immune systems.

Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing innovative treatments for rare cancers. The company is working on a proprietary gel formulation of mechlorethamine hydrochloride aimed at treating early-stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If successful, this investigational drug would be the first topical mechlorethamine product available to alleviate the signs and symptoms associated with this condition. In addition to its primary focus on CTCL, Ceptaris is also advancing YT-1006, an NMDA antagonist designed for treating neuropathic pain while mitigating side effects through a unique stereochemistry approach.

AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

NewBridge Pharmaceuticals Ltd. is a specialty therapeutics company based in Dubai, United Arab Emirates, established in 2007. The company focuses on addressing unmet medical needs in the Middle East, Africa, Turkey, and Caspian regions through the in-licensing, acquisition, registration, and commercialization of pharmaceuticals, biologics, and medical diagnostics. NewBridge offers a diverse portfolio of products that includes oncology and supportive care medications such as Abstral for cancer pain management, Clasteon for bone metastasis and hypercalcemia, and Sancuso for preventing chemotherapy-induced nausea. Additionally, it provides metabolic care treatments like Gliconorm for diabetes and PYLERA for H. pylori eradication. The company's offerings also extend to CNS care products, including Vimpat for seizures and Neupro for Parkinson's disease, as well as immunology care solutions like Cimzia for rheumatoid arthritis. By focusing on therapeutic areas such as oncology, diabetes, and metabolic disorders, NewBridge Pharmaceuticals aims to support patients with critical health challenges in its target regions.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Gevo, Inc. is a renewable fuels company based in Englewood, Colorado, focused on developing and commercializing sustainable alternatives to petroleum-based products. Founded in 2005, Gevo specializes in producing renewable fuels such as gasoline, jet fuel, and diesel, as well as chemicals derived from isobutanol, a key product made from low-carbon renewable feedstocks. The company's offerings include renewable biodiesel, sustainable aviation fuel, isobutylene, ethanol, and animal feed. Gevo is also engaged in producing renewable electricity and natural gas to support its operations. Through its various segments, Gevo conducts research and development aimed at advancing biofuels and biochemicals, including innovative technologies for the production of sustainable aviation fuel and other renewable hydrocarbon products, while actively working to reduce greenhouse gas emissions.

Endocyte, Inc. is a biopharmaceutical company based in West Lafayette, Indiana, focused on developing receptor-targeted therapeutics for cancer and inflammatory diseases. The company specializes in small molecule drug conjugates (SMDCs) and companion imaging agents to enhance treatment efficacy. Key products under development include Vintafolide, which is in a Phase IIb clinical trial for non-small cell lung cancer, and EC1456 and EC1169, both in Phase I trials targeting advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is exploring several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company collaborates with various research institutions and organizations to advance its innovative therapies. Founded in 1995, Endocyte, Inc. operates as a subsidiary of Novartis AG.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

Gevo, Inc. is a renewable fuels company based in Englewood, Colorado, focused on developing and commercializing sustainable alternatives to petroleum-based products. Founded in 2005, Gevo specializes in producing renewable fuels such as gasoline, jet fuel, and diesel, as well as chemicals derived from isobutanol, a key product made from low-carbon renewable feedstocks. The company's offerings include renewable biodiesel, sustainable aviation fuel, isobutylene, ethanol, and animal feed. Gevo is also engaged in producing renewable electricity and natural gas to support its operations. Through its various segments, Gevo conducts research and development aimed at advancing biofuels and biochemicals, including innovative technologies for the production of sustainable aviation fuel and other renewable hydrocarbon products, while actively working to reduce greenhouse gas emissions.

CareDx, Inc. is a precision medicine company that specializes in developing and commercializing innovative healthcare solutions for transplant patients and their caregivers. The company offers a range of molecular diagnostics products, including AlloSure Kidney and AlloMap Heart, which utilize donor-derived cell-free DNA to assess organ transplant health and identify potential rejections noninvasively. CareDx also provides various solutions for human leukocyte antigen typing, chimerism testing, and post-transplant monitoring. Its offerings extend to patient tracking software and predictive analysis tools, enhancing the overall transplant experience from initial matching to ongoing care. Founded in 1998 and headquartered in South San Francisco, California, CareDx has established partnerships for the development and distribution of advanced genomic testing technologies, further solidifying its role as a leader in transplant diagnostics.

Virdia, formerly known as HCL CleanTech, is a prominent developer specializing in the conversion of lignocellulosic biomass into cellulosic sugars and lignin for applications in the renewable chemicals, bio-energy, and nutrition sectors. Utilizing its proprietary CASE™ process, the company transforms a diverse range of feedstocks, including wood, energy crops, and agricultural residues, into highly refined sugars and lignin. This innovative low-temperature process achieves high yields of sugars from biomass while maintaining a minimal environmental impact through the near complete recycling of acids and solvents used during production. Virdia is guided by an experienced management team with extensive backgrounds in corn processing, chemicals, and biochemicals.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Ikano Therapeutics a specialty pharmaceutical company, focuses on developing nasal spray drug products.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

Arete Therapeutics is a pharmaceutical company that develops small molecule therapeutics for diabetes and cardiovascular disease.

Osprey Pharmaceuticals USA, Inc., established in 2008 and headquartered in San Francisco, specializes in developing protein therapeutics to treat inflammatory and immune diseases. Its primary focus is on advancing a pipeline of proprietary fusion proteins called Leukocyte Population Modulators (LPMs), designed to selectively target and neutralize chemokine-activated leukocytes involved in various inflammatory conditions. The company's lead candidate, CCL2-LPM, targeting the CCR2 chemokine receptor, is currently in Phase Ib clinical trials for treating IgA nephropathy, an inflammatory kidney disease.

BioImagene, Inc. is a provider of digital pathology solutions aimed at enhancing clinical diagnostics and drug discovery efforts. Established in 2003 and headquartered in Sunnyvale, California, the company specializes in developing and distributing integrated hardware and software systems designed for the acquisition, management, and analysis of tissue images in pathology laboratories. BioImagene's offerings include immunohistochemistry (IHC) algorithms for various cancers, such as HER2 and Ki67, as well as advanced digital slide scanners like the iScan Coreo Au, which facilitate applications including image analysis and telepathology. The company's solutions cater to a wide range of clients, which include cancer research laboratories, academic medical centers, community hospitals, reference laboratories, and pharmaceutical companies.

Wellpartner is a prominent provider of pharmacy distribution solutions that serves health plans, Medicaid programs, and safety net organizations across the United States. The company specializes in managing 340B program services, focusing on innovative strategies that enhance pharmacy care while reducing medication costs. As the largest independent provider of contract pharmacy program services in the country, Wellpartner offers a range of services, including specialty pharmacy solutions and compliance support, aimed at maximizing the value of healthcare resources. By optimizing contract arrangements and ensuring access to specialty networks, Wellpartner helps healthcare organizations effectively serve more eligible patients and improve the overall quality of pharmacy care.

Gevo, Inc. is a renewable fuels company based in Englewood, Colorado, focused on developing and commercializing sustainable alternatives to petroleum-based products. Founded in 2005, Gevo specializes in producing renewable fuels such as gasoline, jet fuel, and diesel, as well as chemicals derived from isobutanol, a key product made from low-carbon renewable feedstocks. The company's offerings include renewable biodiesel, sustainable aviation fuel, isobutylene, ethanol, and animal feed. Gevo is also engaged in producing renewable electricity and natural gas to support its operations. Through its various segments, Gevo conducts research and development aimed at advancing biofuels and biochemicals, including innovative technologies for the production of sustainable aviation fuel and other renewable hydrocarbon products, while actively working to reduce greenhouse gas emissions.

NanoVasc is a pioneering medical device company specializing in the design and manufacture of biomimetic materials. These materials are engineered to be non-thrombogenic, durable, and capable of maintaining long-term patency. Utilizing an electrospinning process, NanoVasc produces scaffolds in various shapes and sizes, which are then customized with application-specific modifications on the scaffold's surface. These modifications are meticulously crafted to optimize device performance based on its intended deployment location. The company's flagship product is a synthetic vascular graft specifically developed for hemodialysis access. This innovative graft aims to improve patient outcomes by providing a reliable and effective alternative to traditional vascular access methods. NanoVasc's dedication to biomimetic design and precision engineering underscores its commitment to advancing medical solutions that enhance the quality of patient care in vascular health.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

Chlorogen a biopharmaceutical company, engages in the development and manufacture of proteins for human therapy. The company, through its chloroplast transformation technology (CTT), offers plant made drugs for the treatment and prevention of human diseases, as well as for treatment of women's reproductive cancers. Its products include therapeutic proteins in tobacco that are made using chloroplast transformation technology. The chloroplast transformation technology facilitates hyper-expression of recombinant proteins in tobacco chloroplasts. The company offers its chloroplast-tobacco platform for commercial use in food and agriculture. Chlorogen, Inc. was founded in 2002 and is based in St. Louis, Missouri.

Light Sciences Oncology, Inc. is a biotechnology company focused on developing and manufacturing talaporfin sodium, a water-soluble drug for the treatment of solid tumors and other medical indications. The company specializes in providing innovative oncology solutions, including a single-use, LED-based drug activator that delivers a precise light dose to enhance treatment efficacy. Its primary applications include the treatment of hepatocellular carcinoma, metastatic colorectal cancer, and benign prostatic hyperplasia. Founded in 1994 and headquartered in Bellevue, Washington, Light Sciences Oncology combines advanced drug development with a commitment to improving patient care through non-invasive treatment options.

Logical Therapeutics, Inc., a biopharmaceutical company, engages in the development of drugs to treat diseases caused by or associated with excessive inflammation. Its products include LT-NS001, a non-steroidal anti-inflammatory drug for the treatment of chronic inflammatory conditions, such as osteoarthritis; Leptin, a hormone for the regulation of normal body mass and metabolism; and TNF, a hormone that promotes the proliferation of hepatocytes. The company was founded in 2005 and is based in Waltham, Massachusetts.

Phytomedics is committed to quality, technological innovation and research. Their powerful portfolio of overlapping proprietary technologies is targeted to turning green plants into reliable vehicles for discovering and manufacturing proprietary botanical pharmaceuticals and nutraceuticals. NewLeadTM and RhizexTM elicitation and optimization processes greatly enhance the efficacy and reproducibility of plant-derived products and increase the synergy between various chemical components of plant extracts. The Company has developed an efficient and proprietary discovery and lead prioritization process based on high-power bio-informatics, high-tech data mining, efficient activity screening, and an extensive network of international collaborations.

Dreamerz Foods, Inc. provides various natural sleep products. It offers natural sleep beverage, a dietary supplement in the form of an all-natural, creamy, and dairy-based functional sleep beverage. The company also provides chocolate pillows, soothing dairy products, and herbal fruit-flavored mix. It offers its products through stores and online shops. Dreamerz Foods, Inc. was founded in 2006 and is based in San Francisco, California.

Arete Therapeutics is a pharmaceutical company that develops small molecule therapeutics for diabetes and cardiovascular disease.

The Natural Dentist, Inc., founded in 1995 and based in Medford, Massachusetts, is a manufacturer of oral care products, including mouth rinses and toothpastes. Initially established as Woodstock Natural Products Inc., the company rebranded in 2005 to focus on natural and effective solutions for dental hygiene. The Natural Dentist provides its products through various channels, including retail stores, online platforms, and direct phone orders. In 2010, the company was acquired by Revive Personal Products Company, which expanded its reach within the consumer healthcare market. The Natural Dentist emphasizes the importance of quality oral care, catering to health-conscious consumers seeking natural alternatives.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Attune Foods, Inc. is a producer of organic snacks headquartered in San Francisco, California, with a focus on probiotic wellness products. Founded in 2006, the company offers a diverse range of wellness bars in multiple flavors, including dark chocolate, mint chocolate, blueberry vanilla, and chewy options such as chocolate peanut butter and mango peach. In addition to wellness bars, Attune Foods also provides granolas featuring chocolate or yogurt chips, muesli, cereals, and graham crackers. The company's mission is to support customers in their pursuit of healthy eating through customizable food options.

Endocyte, Inc. is a biopharmaceutical company based in West Lafayette, Indiana, focused on developing receptor-targeted therapeutics for cancer and inflammatory diseases. The company specializes in small molecule drug conjugates (SMDCs) and companion imaging agents to enhance treatment efficacy. Key products under development include Vintafolide, which is in a Phase IIb clinical trial for non-small cell lung cancer, and EC1456 and EC1169, both in Phase I trials targeting advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is exploring several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company collaborates with various research institutions and organizations to advance its innovative therapies. Founded in 1995, Endocyte, Inc. operates as a subsidiary of Novartis AG.

ProteoGenix is a company focused on the development and commercialization of diagnostic testing products tailored for the maternal-fetal health sector. Founded in 2002 and headquartered in Costa Mesa, California, with additional offices in Beaverton and Orange County, the company specializes in non-invasive diagnostic tests. These tests aim to detect critical health issues such as intraamniotic infection, neonatal sepsis, preterm birth, preeclampsia, and Down syndrome, thereby providing essential tools for healthcare professionals in monitoring and managing maternal and fetal well-being.

diaDexus is a privately held biotechnology company based in the United States, specializing in the discovery, development, and commercialization of innovative diagnostic products with significant clinical relevance. The company's flagship product, the PLAC Test, assesses levels of Lp-PLA2, an enzyme linked to the formation of harmful plaque in blood vessels, which is a key factor in cardiovascular events like heart disease and stroke. The PLAC Test is unique as it is the only FDA-cleared blood test that aids in evaluating the risk for coronary heart disease and ischemic stroke related to atherosclerosis. In addition to cardiovascular diagnostics, diaDexus offers test kits for various conditions, including liver disease, cancer markers, renal disease, diabetes, and electrolyte imbalances. The company primarily operates in the United States, with a growing presence in Europe and other regions worldwide.

Dreamerz Foods, Inc. provides various natural sleep products. It offers natural sleep beverage, a dietary supplement in the form of an all-natural, creamy, and dairy-based functional sleep beverage. The company also provides chocolate pillows, soothing dairy products, and herbal fruit-flavored mix. It offers its products through stores and online shops. Dreamerz Foods, Inc. was founded in 2006 and is based in San Francisco, California.

The Natural Dentist, Inc., founded in 1995 and based in Medford, Massachusetts, is a manufacturer of oral care products, including mouth rinses and toothpastes. Initially established as Woodstock Natural Products Inc., the company rebranded in 2005 to focus on natural and effective solutions for dental hygiene. The Natural Dentist provides its products through various channels, including retail stores, online platforms, and direct phone orders. In 2010, the company was acquired by Revive Personal Products Company, which expanded its reach within the consumer healthcare market. The Natural Dentist emphasizes the importance of quality oral care, catering to health-conscious consumers seeking natural alternatives.

Neurotech is a privately held biotechnology company focused on developing innovative therapeutics for chronic retinal diseases, which are characterized by significant unmet medical needs. The company has created a novel therapy system that features an ocular implant designed to continuously produce therapeutic proteins within the eye. This technology allows therapeutic cells to endure challenging conditions associated with these diseases, effectively replacing or supporting the function of damaged target cells or tissue. By doing so, Neurotech aims to enhance the quality of life for individuals suffering from chronic retinal disorders, addressing a substantial market opportunity within the field of ophthalmology.

Endocyte, Inc. is a biopharmaceutical company based in West Lafayette, Indiana, focused on developing receptor-targeted therapeutics for cancer and inflammatory diseases. The company specializes in small molecule drug conjugates (SMDCs) and companion imaging agents to enhance treatment efficacy. Key products under development include Vintafolide, which is in a Phase IIb clinical trial for non-small cell lung cancer, and EC1456 and EC1169, both in Phase I trials targeting advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is exploring several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company collaborates with various research institutions and organizations to advance its innovative therapies. Founded in 1995, Endocyte, Inc. operates as a subsidiary of Novartis AG.

Morphotek, established in 2000, is a prominent life science company specializing in developing novel biological products to combat cancer, inflammation, and infectious diseases. The company's core technology, morphogenics, was co-invented by its current President and CEO, Dr. Nicholas Nicolaides, during his postgraduate research at Johns Hopkins Medical School. Morphotek focuses on discovering and developing monoclonal antibodies (mAbs) using this proprietary technology to treat various conditions such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. The company conducts independent research and clinical development programs for its drug candidates.

CardioKine, Inc. is a specialty pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company focuses on developing innovative pharmaceuticals aimed at the prevention and treatment of cardiovascular diseases. One of its notable products is lixivaptan, an orally active vasopressin receptor antagonist designed for patients with congestive heart failure who experience hyponatremia. CardioKine is dedicated to addressing unmet medical needs in cardiovascular health through its targeted therapeutic compounds.

Sciona provides gene-based personalized health and nutrition analysis and recommendations based on individual diet, lifestyle, and genetic profile. The company's Mycellf Program, which includes a diet and lifestyle questionnaire, makes recommendations for how individuals can make choices that benefit their long-term health. It also offers genetic testing products, which address personal wellness, fitness, and nutritional issues. The company was founded in 2000 and is headquartered in Aurora, Colorado.

Chromatin is a biotech company focused on developing and marketing innovative technologies and products across agricultural, energy, chemical, nutritional, and pharmaceutical sectors. The company specializes in hybrid, drought-tolerant sorghum seeds, utilizing advanced breeding methodologies to create next-generation sorghum that meets the rising demand for sustainable agricultural practices. By combining diverse sorghum varieties, Chromatin produces seeds that can thrive on more than 80% of the world's agricultural land, supporting farmers in optimizing crop production for both traditional agriculture and bio-industrial applications. The company aims to address key societal challenges, enhancing agricultural productivity and contributing to renewable energy resources.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

Adlyfe is a biotechnology company established in 2003, dedicated to the development of innovative diagnostic products for neurodegenerative diseases linked to amyloidogenesis. This process involves the misfolding of normally soluble proteins, leading to their aggregation and deposition in brain tissue, which ultimately results in the loss of neural cells and brain tissue. Adlyfe specializes in creating biomarkers and diagnostic tests aimed at detecting human neurodegenerative conditions, including sporadic and variant Creutzfeldt-Jakob disease, as well as transmissible spongiform encephalopathy (TSE) diseases in animals. By focusing on these critical health issues, Adlyfe aims to enhance patient outcomes through timely and accurate detection of these debilitating diseases.

Ikano Therapeutics a specialty pharmaceutical company, focuses on developing nasal spray drug products.

CareDx, Inc. is a precision medicine company that specializes in developing and commercializing innovative healthcare solutions for transplant patients and their caregivers. The company offers a range of molecular diagnostics products, including AlloSure Kidney and AlloMap Heart, which utilize donor-derived cell-free DNA to assess organ transplant health and identify potential rejections noninvasively. CareDx also provides various solutions for human leukocyte antigen typing, chimerism testing, and post-transplant monitoring. Its offerings extend to patient tracking software and predictive analysis tools, enhancing the overall transplant experience from initial matching to ongoing care. Founded in 1998 and headquartered in South San Francisco, California, CareDx has established partnerships for the development and distribution of advanced genomic testing technologies, further solidifying its role as a leader in transplant diagnostics.

Alinea Pharmaceuticals, Inc., a biopharmaceutical company previously focused on developing new therapeutics for the treatment of diabetes and other metabolic disorders.

Chlorogen a biopharmaceutical company, engages in the development and manufacture of proteins for human therapy. The company, through its chloroplast transformation technology (CTT), offers plant made drugs for the treatment and prevention of human diseases, as well as for treatment of women's reproductive cancers. Its products include therapeutic proteins in tobacco that are made using chloroplast transformation technology. The chloroplast transformation technology facilitates hyper-expression of recombinant proteins in tobacco chloroplasts. The company offers its chloroplast-tobacco platform for commercial use in food and agriculture. Chlorogen, Inc. was founded in 2002 and is based in St. Louis, Missouri.

BioMimetic Therapeutics is a biotechnology company based in Franklin, Tennessee, founded in 1999. The company focuses on the development of biologically active drug-device combination products designed to stimulate the body's natural tissue regenerative processes. Its product portfolio includes Augment Injectable and Augment Rotator Cuff, which target various orthopedic and sports medicine conditions. These products are utilized for treating foot and ankle fusions, facilitating wrist fracture healing, and addressing surgical interventions for rotator cuff tears. Additionally, BioMimetic Therapeutics offers the Augment Tendinopathy Injection, aimed at managing injuries resulting from tendon overuse. The company is dedicated to advancing solutions for the healing of injuries and diseases affecting the skeleton and associated tissues.

Brand New Brands is a groundbreaking new company that brings together the entrepreneurial spirit of a start-up and the resources of an established corporation to create new foods and beverages that promote health and wellness. Brand New Brands uses a portfolio-based incubator model to develop and market the highest potential new functional food business opportunities for the U.S. marketplace. Core to their approach is the commitment to create food and beverage products that are efficacious (by medical standards), honest and transparent in their claims, and satisfying to eat or drink. By vetting and assessing the potential of scores of new product concepts, they take the most promising opportunities and fuse them with talented, passionate and proven entrepreneurial teams who turn ideas into thriving new ventures. They focus their efforts and resources by innovating “category-creating” brand platforms that are capable of crossing over from niche markets to the mainstream in three to five years. They only pursue opportunities where they can claim distinct competitive advantages over large food companies through IP, brand creation or non-traditional distribution. Their strategy is to take the most promising new nutritional technologies and deliver them to the marketplace through great-tasting products with engaging “lifestyle” brands that educate and attract loyal customers and progressive retail partners. They take opportunities to market that are likely to scale quickly due to the convergence of scientific advances, consumer readiness and media attention.

Alexza Pharmaceuticals, Inc. is a pharmaceutical company based in Mountain View, California, dedicated to the research, development, and commercialization of proprietary products for the acute treatment of central nervous system conditions. The company utilizes its innovative Staccato system, a hand-held inhaler that vaporizes drugs into a condensation aerosol for rapid systemic delivery when inhaled. Its primary product, ADASUVE, contains Staccato loxapine and is intended for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Additionally, Alexza is developing AZ-002, which is Staccato alprazolam for acute repetitive seizures, and AZ-007, Staccato zaleplon for insomnia. The company was founded in 2001 and was formerly known as Alexza Molecular Delivery Corporation before rebranding in 2005. As of 2016, it operates as a subsidiary of Ferrer Therapeutics, Inc.

CareDx, Inc. is a precision medicine company that specializes in developing and commercializing innovative healthcare solutions for transplant patients and their caregivers. The company offers a range of molecular diagnostics products, including AlloSure Kidney and AlloMap Heart, which utilize donor-derived cell-free DNA to assess organ transplant health and identify potential rejections noninvasively. CareDx also provides various solutions for human leukocyte antigen typing, chimerism testing, and post-transplant monitoring. Its offerings extend to patient tracking software and predictive analysis tools, enhancing the overall transplant experience from initial matching to ongoing care. Founded in 1998 and headquartered in South San Francisco, California, CareDx has established partnerships for the development and distribution of advanced genomic testing technologies, further solidifying its role as a leader in transplant diagnostics.

Neosil, Inc. is a pharmaceutical company specializing in dermatology, focusing on the development of innovative topical products. The company has successfully created a topical hair growth treatment and is also advancing a broad-spectrum topical anti-microbial agent aimed at treating acne and preventing infections. Neosil's core technology offers extensive anti-infective properties, ensuring prolonged effectiveness and versatility in formulation. Through its research and development efforts, Neosil is dedicated to addressing unmet needs in dermatological treatments.

BioMimetic Therapeutics is a biotechnology company based in Franklin, Tennessee, founded in 1999. The company focuses on the development of biologically active drug-device combination products designed to stimulate the body's natural tissue regenerative processes. Its product portfolio includes Augment Injectable and Augment Rotator Cuff, which target various orthopedic and sports medicine conditions. These products are utilized for treating foot and ankle fusions, facilitating wrist fracture healing, and addressing surgical interventions for rotator cuff tears. Additionally, BioMimetic Therapeutics offers the Augment Tendinopathy Injection, aimed at managing injuries resulting from tendon overuse. The company is dedicated to advancing solutions for the healing of injuries and diseases affecting the skeleton and associated tissues.

Sciona provides gene-based personalized health and nutrition analysis and recommendations based on individual diet, lifestyle, and genetic profile. The company's Mycellf Program, which includes a diet and lifestyle questionnaire, makes recommendations for how individuals can make choices that benefit their long-term health. It also offers genetic testing products, which address personal wellness, fitness, and nutritional issues. The company was founded in 2000 and is headquartered in Aurora, Colorado.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Nucleonics is a biotechnology company focused on RNA interference-based therapeutics.

Efficas, Inc. is a health-science and technology company based in Boulder, Colorado, founded in 2003. The company specializes in the research, development, and commercialization of products designed for the nutritional management of the immune system in both humans and pets. Efficas offers EFFICAS CARE, a berry-flavored non-prescription medical food aimed at the dietary management of asthma and related allergies. The company's products are formulated to work with the body's natural systems, providing safe and effective relief from asthma and allergic conditions, thereby enhancing overall health benefits for its users.

CardioKine, Inc. is a specialty pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company focuses on developing innovative pharmaceuticals aimed at the prevention and treatment of cardiovascular diseases. One of its notable products is lixivaptan, an orally active vasopressin receptor antagonist designed for patients with congestive heart failure who experience hyponatremia. CardioKine is dedicated to addressing unmet medical needs in cardiovascular health through its targeted therapeutic compounds.

Spectral Genomics, based in Houston, Texas, specializes in developing innovative products and services in the field of molecular genetics and diagnostics. The company is recognized for its pioneering technology in genomic profiling, offering services tailored for both academic and industrial research laboratories. By focusing on human genetics, Spectral Genomics aims to advance the understanding of genetic information and its applications in various research contexts.

Morphotek, established in 2000, is a prominent life science company specializing in developing novel biological products to combat cancer, inflammation, and infectious diseases. The company's core technology, morphogenics, was co-invented by its current President and CEO, Dr. Nicholas Nicolaides, during his postgraduate research at Johns Hopkins Medical School. Morphotek focuses on discovering and developing monoclonal antibodies (mAbs) using this proprietary technology to treat various conditions such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. The company conducts independent research and clinical development programs for its drug candidates.

Phytomedics is committed to quality, technological innovation and research. Their powerful portfolio of overlapping proprietary technologies is targeted to turning green plants into reliable vehicles for discovering and manufacturing proprietary botanical pharmaceuticals and nutraceuticals. NewLeadTM and RhizexTM elicitation and optimization processes greatly enhance the efficacy and reproducibility of plant-derived products and increase the synergy between various chemical components of plant extracts. The Company has developed an efficient and proprietary discovery and lead prioritization process based on high-power bio-informatics, high-tech data mining, efficient activity screening, and an extensive network of international collaborations.

Immunicon is a developer and manufacturer of proprietary cell-based diagnostic and research products, primarily focusing on cancer detection and monitoring. The company specializes in ultra-high sensitivity cancer detection test kits and next-generation cell analysis instruments. Their technologies, branded as CellTracks, are designed to identify, count, and characterize tumor cells in blood samples, providing physicians with clinically meaningful information earlier than traditional diagnostic methods. A notable collaboration with Veridex, a Johnson & Johnson company, has led to the submission of a pre-market notification for the CellSearch Epithelial Cell Kit, aimed at enhancing the management of metastatic breast cancer. Immunicon believes its technologies not only hold promise for cancer diagnostics but may also be applicable in other medical fields, including cardiovascular and infectious diseases, thereby contributing to the advancement of medical research and treatment.

BioMimetic Therapeutics is a biotechnology company based in Franklin, Tennessee, founded in 1999. The company focuses on the development of biologically active drug-device combination products designed to stimulate the body's natural tissue regenerative processes. Its product portfolio includes Augment Injectable and Augment Rotator Cuff, which target various orthopedic and sports medicine conditions. These products are utilized for treating foot and ankle fusions, facilitating wrist fracture healing, and addressing surgical interventions for rotator cuff tears. Additionally, BioMimetic Therapeutics offers the Augment Tendinopathy Injection, aimed at managing injuries resulting from tendon overuse. The company is dedicated to advancing solutions for the healing of injuries and diseases affecting the skeleton and associated tissues.

Emerald BioAgriculture Corporation is a privately held company based in Hockessin, Delaware, focused on developing specialty nutritional technologies and biochemical products aimed at enhancing agricultural productivity. Founded in 1994 and formerly known as Auxein Corporation, the company specializes in creating naturally occurring biochemicals that improve crop yields, quality, and disease resistance. By providing innovative solutions to agricultural product manufacturers, Emerald BioAgriculture aims to support sustainable farming practices and contribute to increased crop production globally.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

Alexza Pharmaceuticals, Inc. is a pharmaceutical company based in Mountain View, California, dedicated to the research, development, and commercialization of proprietary products for the acute treatment of central nervous system conditions. The company utilizes its innovative Staccato system, a hand-held inhaler that vaporizes drugs into a condensation aerosol for rapid systemic delivery when inhaled. Its primary product, ADASUVE, contains Staccato loxapine and is intended for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Additionally, Alexza is developing AZ-002, which is Staccato alprazolam for acute repetitive seizures, and AZ-007, Staccato zaleplon for insomnia. The company was founded in 2001 and was formerly known as Alexza Molecular Delivery Corporation before rebranding in 2005. As of 2016, it operates as a subsidiary of Ferrer Therapeutics, Inc.

GeneFormatics is a biotechnology company that focuses on structural proteomics. It develops innovative function prediction methods aimed at the rapid identification of biologically relevant targets from extensive sequence data generated by global genomics projects. By harnessing advanced computational techniques, GeneFormatics contributes to the understanding of protein structures and functions, facilitating breakthroughs in biological research and potential therapeutic applications.

Morphotek, established in 2000, is a prominent life science company specializing in developing novel biological products to combat cancer, inflammation, and infectious diseases. The company's core technology, morphogenics, was co-invented by its current President and CEO, Dr. Nicholas Nicolaides, during his postgraduate research at Johns Hopkins Medical School. Morphotek focuses on discovering and developing monoclonal antibodies (mAbs) using this proprietary technology to treat various conditions such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. The company conducts independent research and clinical development programs for its drug candidates.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

BioMimetic Therapeutics is a biotechnology company based in Franklin, Tennessee, founded in 1999. The company focuses on the development of biologically active drug-device combination products designed to stimulate the body's natural tissue regenerative processes. Its product portfolio includes Augment Injectable and Augment Rotator Cuff, which target various orthopedic and sports medicine conditions. These products are utilized for treating foot and ankle fusions, facilitating wrist fracture healing, and addressing surgical interventions for rotator cuff tears. Additionally, BioMimetic Therapeutics offers the Augment Tendinopathy Injection, aimed at managing injuries resulting from tendon overuse. The company is dedicated to advancing solutions for the healing of injuries and diseases affecting the skeleton and associated tissues.

Bruker Corporation is a leading provider of high-performance scientific instruments and solutions tailored for molecular and materials research, as well as industrial and applied analysis. The company manufactures a range of scientific instruments and diagnostic tests primarily for clients in the life sciences, pharmaceutical, and biotechnology sectors. Bruker operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST), with the BSI CALID segment generating the highest revenue. The company has a significant revenue presence in the Asia Pacific region, reflecting its global reach and commitment to advancing scientific research and innovation. Additionally, Bruker Cellular Analysis focuses on cell biology, facilitating the exploration of cellular phenomes and the mastery of single-cell analysis for laboratories.

Circe Biomedical, Inc. is a Lexington, Massachusetts-based company that specializes in the development, production, and commercialization of bioartificial organ systems. Founded in 1999, Circe Biomedical focuses on creating bioartificial organs using isolated mammalian cells and membranes, particularly for patients experiencing acute, end-stage liver failure. One of its key products is the HepatAssist® Liver Support System, which combines viable liver cells with biocompatible membranes to form an extracorporeal liver assist system. Additionally, the company is developing the PancreAssist System, an implantable bioartificial pancreas designed for individuals with severe insulin-dependent diabetes.

GeneFormatics is a biotechnology company that focuses on structural proteomics. It develops innovative function prediction methods aimed at the rapid identification of biologically relevant targets from extensive sequence data generated by global genomics projects. By harnessing advanced computational techniques, GeneFormatics contributes to the understanding of protein structures and functions, facilitating breakthroughs in biological research and potential therapeutic applications.

In December 1999, Pangea Systems became DoubleTwist, Inc. - a new application service provider (ASP)/ Internet company devoted to empowering life scientists. The change reflects a new focus on this Internet portal. DoubleTwist.com integrates powerful tools and data behind automated research agents that retrieve and interpret data based on the user's scientific questions. The company's traditional data warehousing and mining software power the site, enabling life science research through an easy-to-use interface on the Web. DoubleTwist has established a talented and experienced development team of scientific and technical personnel dedicated to building software solutions that address the biological data management needs of life scientists. DoubleTwist's scientific team is comprised of leading experts in their respective fields of biochemistry, molecular biology, protein chemistry, bioinformatics, computer science and computational biology. They come to DoubleTwist from world-renowned institutions, including Stanford University, UCLA, UC Berkeley, UCSF, University of Pennsylvania, Sandoz Pharmaceutical, Onyx Pharmaceutical, Incyte, Molecular Simulations, Molecular Dynamics, Roche and Glaxo Wellcome. The company's software engineers have extensive experience in commercial-grade software systems, with particular expertise in relational database and object-oriented development. They come to DoubleTwist from some of the industry's most successful companies, including Apple, Oracle and IBM.